Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 30, 2015 6:00 AM ET

Biotechnology

Company Overview of Oscient Pharmaceuticals Corp.

Executive Profile

Dominick C. Colangelo Esq.

Chief Executive Officer, President, Treasurer and Director, Vericel Corporation
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 6 different industries.

See Board Relationships
50$935,939
As of Fiscal Year 2014

Background

Mr. Dominick C. Colangelo, also known as Nick, Esq. has been the Chief Executive Officer and President at Vericel Corporation. since March 1, 2013 and as its Chief Administrative Officer and Treasurer since May 7, 2014. Mr. Colangello served as Managing Director of Lilly BioVentures and Lilly Venture Funds. Mr. Colangello was responsible for directing Lilly's venture investing activities. He led investments in Xenoport, NexCura, Zyomyx, and Fast Track Systems. He joined ...

Corporate Headquarters

1000 Winter Street
Waltham, Massachusetts 02451

United States

Phone: 781-398-2300
Fax: 781-893-9535

Board Members Memberships

Former Director
Former Director
Director
Former Director
2009-2012
Former Chief Executive Officer, President and Director
2013-Present
Chief Executive Officer, President, Treasurer and Director

Education

BSBA
University at Buffalo
JD
Duke University School of Law

Other Affiliations

Annual Compensation

Salary$430,000
Bonus$89,583
Total Annual Compensation$519,583

Stocks Options

All Other Compensation$39,633
Exercisable Options$24,063
Unexercisable Options$30,938
Total Number of Options$55,001

Total Compensation

Total Annual Cash Compensation$795,716
Total Short Term Compensation$519,583
Other Long Term Compensation$39,633
Total Calculated Compensation$935,939
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robin C. Stracey Interim Chief Executive Officer, Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Governance & Nominating Committee
Cesca Therapeutics Inc.
--
Olav Hellebo Chief Executive Officer
ReNeuron Group plc
--
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$437.4K
David J. Mazzo B.A (Hons), B.Sc. (Hons.), M.Sc., Ph.D.Chief Executive Officer and Director
Neostem, Inc.
--
Eduardo Bravo Fernández de Araoz Chief Executive Officer, Managing Director and Director
TiGenix N.V.
$433.6K
Compensation as of Fiscal Year --.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oscient Pharmaceuticals Corp., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.